Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. September 2013 12:59 ET | Quelle: Mateon Therapeutics

OXiGENE to Present at 12th Annual BIO Investor Forum Conference on October 8, 2013

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
19. September 2013 12:40 ET | Quelle: Mateon Therapeutics

OXiGENE Announces $5.8 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that it...
03. September 2013 16:30 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Presentation at the 15th Annual Rodman & Renshaw Global Investment Conference on September 9th

SOUTH SAN FRANCISCO, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
06. August 2013 16:10 ET | Quelle: Mateon Therapeutics

OXiGENE Reports Second Quarter 2013 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
24. Juli 2013 16:00 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Second Quarter 2013 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., July 24, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report second...
18. Juli 2013 16:11 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Granting of Orphan Drug Status in Europe for ZYBRESTAT in Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., July 18, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that the...
10. Juni 2013 09:00 ET | Quelle: Mateon Therapeutics

OXIGENE Announces Publication of Final FACT Study Data in Journal Thyroid Suggest Survival Benefit of ZYBRESTAT(R) in Patients With Anaplastic Thyroid Cancer

SOUTH SAN FRANCISCO, Calif., June 10, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer, announced the...
06. Mai 2013 16:00 ET | Quelle: Mateon Therapeutics

OXiGENE Reports First Quarter 2013 Financial Results

SOUTH SAN FRANCISCO, Calif., May 6, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial...
24. April 2013 16:00 ET | Quelle: Mateon Therapeutics

OXiGENE Announces Completion of Enrollment of ZYBRESTAT(R) Phase 2 Ovarian Cancer Trial

SOUTH SAN FRANCISCO, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that...
24. April 2013 06:30 ET | Quelle: Mateon Therapeutics

OXiGENE Announces First Quarter 2013 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, will report first...

Vorherige Seite